FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1464936406> ?p ?o ?g. }

• W1464936406 endingPage "219" @default.
• W1464936406 startingPage "209" @default.
• W1464936406 abstract "Growth of hormone-receptor-positive breast cancer is dependent on cyclin-dependent kinases 4 and 6 (CDK4 and CDK6), which promote progression from the G1 phase to the S phase of the cell cycle. We assessed the efficacy of palbociclib (an inhibitor of CDK4 and CDK6) and fulvestrant in advanced breast cancer.This phase 3 study involved 521 patients with advanced hormone-receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that had relapsed or progressed during prior endocrine therapy. We randomly assigned patients in a 2:1 ratio to receive palbociclib and fulvestrant or placebo and fulvestrant. Premenopausal or perimenopausal women also received goserelin. The primary end point was investigator-assessed progression-free survival. Secondary end points included overall survival, objective response, rate of clinical benefit, patient-reported outcomes, and safety. A preplanned interim analysis was performed by an independent data and safety monitoring committee after 195 events of disease progression or death had occurred.The median progression-free survival was 9.2 months (95% confidence interval [CI], 7.5 to not estimable) with palbociclib-fulvestrant and 3.8 months (95% CI, 3.5 to 5.5) with placebo-fulvestrant (hazard ratio for disease progression or death, 0.42; 95% CI, 0.32 to 0.56; P<0.001). The most common grade 3 or 4 adverse events in the palbociclib-fulvestrant group were neutropenia (62.0%, vs. 0.6% in the placebo-fulvestrant group), leukopenia (25.2% vs. 0.6%), anemia (2.6% vs. 1.7%), thrombocytopenia (2.3% vs. 0%), and fatigue (2.0% vs. 1.2%). Febrile neutropenia was reported in 0.6% of palbociclib-treated patients and 0.6% of placebo-treated patients. The rate of discontinuation due to adverse events was 2.6% with palbociclib and 1.7% with placebo.Among patients with hormone-receptor-positive metastatic breast cancer who had progression of disease during prior endocrine therapy, palbociclib combined with fulvestrant resulted in longer progression-free survival than fulvestrant alone. (Funded by Pfizer; PALOMA3 ClinicalTrials.gov number, NCT01942135.)." @default.
• W1464936406 created "2016-06-24" @default.
• W1464936406 creator A5001814176 @default.
• W1464936406 creator A5008549101 @default.
• W1464936406 creator A5010278367 @default.
• W1464936406 creator A5027231412 @default.
• W1464936406 creator A5030064573 @default.
• W1464936406 creator A5032987754 @default.
• W1464936406 creator A5046221783 @default.
• W1464936406 creator A5047768231 @default.
• W1464936406 creator A5048598383 @default.
• W1464936406 creator A5051676656 @default.
• W1464936406 creator A5060044961 @default.
• W1464936406 creator A5075711437 @default.
• W1464936406 creator A5075821163 @default.
• W1464936406 creator A5087559224 @default.
• W1464936406 date "2015-07-16" @default.
• W1464936406 modified "2023-10-13" @default.
• W1464936406 title "Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer" @default.
• W1464936406 cites W1961026612 @default.
• W1464936406 cites W1985389450 @default.
• W1464936406 cites W2004530391 @default.
• W1464936406 cites W2016569614 @default.
• W1464936406 cites W2019607817 @default.
• W1464936406 cites W2019909594 @default.
• W1464936406 cites W2021145743 @default.
• W1464936406 cites W2023553115 @default.
• W1464936406 cites W2033672070 @default.
• W1464936406 cites W2046410395 @default.
• W1464936406 cites W2057272791 @default.
• W1464936406 cites W2067873262 @default.
• W1464936406 cites W2073367400 @default.
• W1464936406 cites W2089655089 @default.
• W1464936406 cites W2098270787 @default.
• W1464936406 cites W2100808408 @default.
• W1464936406 cites W2114107283 @default.
• W1464936406 cites W2137177885 @default.
• W1464936406 cites W2142334766 @default.
• W1464936406 cites W2144790402 @default.
• W1464936406 cites W2148345265 @default.
• W1464936406 cites W2161551022 @default.
• W1464936406 cites W2167188058 @default.
• W1464936406 cites W2169649287 @default.
• W1464936406 doi "https://doi.org/10.1056/nejmoa1505270" @default.
• W1464936406 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26488700" @default.
• W1464936406 hasPublicationYear "2015" @default.
• W1464936406 type Work @default.
• W1464936406 sameAs 1464936406 @default.
• W1464936406 citedByCount "1150" @default.
• W1464936406 countsByYear W14649364062015 @default.
• W1464936406 countsByYear W14649364062016 @default.
• W1464936406 countsByYear W14649364062017 @default.
• W1464936406 countsByYear W14649364062018 @default.
• W1464936406 countsByYear W14649364062019 @default.
• W1464936406 countsByYear W14649364062020 @default.
• W1464936406 countsByYear W14649364062021 @default.
• W1464936406 countsByYear W14649364062022 @default.
• W1464936406 countsByYear W14649364062023 @default.
• W1464936406 crossrefType "journal-article" @default.
• W1464936406 hasAuthorship W1464936406A5001814176 @default.
• W1464936406 hasAuthorship W1464936406A5008549101 @default.
• W1464936406 hasAuthorship W1464936406A5010278367 @default.
• W1464936406 hasAuthorship W1464936406A5027231412 @default.
• W1464936406 hasAuthorship W1464936406A5030064573 @default.
• W1464936406 hasAuthorship W1464936406A5032987754 @default.
• W1464936406 hasAuthorship W1464936406A5046221783 @default.
• W1464936406 hasAuthorship W1464936406A5047768231 @default.
• W1464936406 hasAuthorship W1464936406A5048598383 @default.
• W1464936406 hasAuthorship W1464936406A5051676656 @default.
• W1464936406 hasAuthorship W1464936406A5060044961 @default.
• W1464936406 hasAuthorship W1464936406A5075711437 @default.
• W1464936406 hasAuthorship W1464936406A5075821163 @default.
• W1464936406 hasAuthorship W1464936406A5087559224 @default.
• W1464936406 hasBestOaLocation W14649364061 @default.
• W1464936406 hasConcept C121608353 @default.
• W1464936406 hasConcept C126322002 @default.
• W1464936406 hasConcept C142724271 @default.
• W1464936406 hasConcept C143998085 @default.
• W1464936406 hasConcept C203092338 @default.
• W1464936406 hasConcept C204787440 @default.
• W1464936406 hasConcept C207103383 @default.
• W1464936406 hasConcept C27081682 @default.
• W1464936406 hasConcept C2775860665 @default.
• W1464936406 hasConcept C2775930923 @default.
• W1464936406 hasConcept C2776694085 @default.
• W1464936406 hasConcept C2777063308 @default.
• W1464936406 hasConcept C2777176818 @default.
• W1464936406 hasConcept C2779744173 @default.
• W1464936406 hasConcept C2780482068 @default.
• W1464936406 hasConcept C44249647 @default.
• W1464936406 hasConcept C530470458 @default.
• W1464936406 hasConcept C535046627 @default.
• W1464936406 hasConcept C71924100 @default.
• W1464936406 hasConcept C84606932 @default.
• W1464936406 hasConceptScore W1464936406C121608353 @default.
• W1464936406 hasConceptScore W1464936406C126322002 @default.
• W1464936406 hasConceptScore W1464936406C142724271 @default.
• W1464936406 hasConceptScore W1464936406C143998085 @default.

• next